Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LMAONASDAQ:LUCDNASDAQ:STIMNASDAQ:TELA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLMAOLMF Acquisition Opportunities$12.35$10.83$5.72▼$22.00$140.05M-0.0150,946 shs560,236 shsLUCDLucid Diagnostics$0.80$1.09$0.76▼$1.85$38.55M1.63247,819 shs116,108 shsSTIMNeuronetics$3.80-0.8%$3.89$1.03▼$5.07$114.80M2.44180,665 shs48,572 shsTELATELA Bio$4.75-7.8%$5.93$4.23▼$11.26$126.94M0.95189,685 shs119,454 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLMAOLMF Acquisition Opportunities0.00%0.00%0.00%0.00%0.00%LUCDLucid Diagnostics-0.44%-1.55%-28.24%-45.07%-50.22%STIMNeuronetics-0.78%-12.04%-11.63%+14.46%+74.31%TELATELA Bio-7.77%-3.46%-13.79%-30.30%-48.54%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLMAOLMF Acquisition OpportunitiesN/AN/AN/AN/AN/AN/AN/AN/ALUCDLucid Diagnostics1.8945 of 5 stars3.53.00.00.02.61.70.0STIMNeuronetics1.8763 of 5 stars3.33.00.00.02.11.70.6TELATELA Bio1.6792 of 5 stars3.52.00.00.01.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLMAOLMF Acquisition OpportunitiesN/AN/AN/AN/ALUCDLucid Diagnostics3.00Buy$2.75245.26% UpsideSTIMNeuronetics2.50Moderate Buy$8.00110.53% UpsideTELATELA Bio3.00Buy$13.67187.72% UpsideCurrent Analyst RatingsLatest STIM, LMAO, TELA, and LUCD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.503/27/2024LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$3.80 ➝ $3.003/27/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.503/26/2024STIMNeuroneticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/22/2024TELATELA BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.003/22/2024TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.003/6/2024STIMNeuroneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLMAOLMF Acquisition OpportunitiesN/AN/AN/AN/A($0.93) per shareN/ALUCDLucid Diagnostics$2.43M15.81N/AN/A($0.47) per share-1.69STIMNeuronetics$71.35M1.60N/AN/A$1.18 per share3.22TELATELA Bio$58.45M2.00N/AN/A$0.77 per share6.17Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLMAOLMF Acquisition Opportunities$80KN/A0.00∞N/AN/A-44.29%3.70%N/ALUCDLucid Diagnostics-$52.67M-$1.27N/A∞N/A-2,169.07%-901.79%-121.11%5/20/2024 (Estimated)STIMNeuronetics-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)TELATELA Bio-$46.66M-$2.07N/AN/AN/A-79.83%-201.62%-58.60%5/9/2024 (Estimated)Latest STIM, LMAO, TELA, and LUCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023LUCDLucid DiagnosticsN/A-$0.26-$0.26-$0.26N/A$1.04 million 3/21/2024Q4 2023TELATELA Bio-$0.44-$0.53-$0.09-$0.53$16.65 million$17.00 million3/5/202412/31/2023STIMNeuronetics-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLMAOLMF Acquisition OpportunitiesN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLMAOLMF Acquisition OpportunitiesN/A14.3514.35LUCDLucid DiagnosticsN/A0.750.74STIMNeuronetics1.734.734.33TELATELA Bio2.154.233.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLMAOLMF Acquisition Opportunities85.03%LUCDLucid Diagnostics74.01%STIMNeuronetics53.59%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipLMAOLMF Acquisition OpportunitiesN/ALUCDLucid Diagnostics4.80%STIMNeuronetics7.30%TELATELA Bio5.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLMAOLMF Acquisition OpportunitiesN/A11.34 millionN/ANot OptionableLUCDLucid Diagnostics7048.24 million45.93 millionNo DataSTIMNeuronetics20329.98 million27.79 millionOptionableTELATELA Bio22724.65 million23.25 millionOptionableSTIM, LMAO, TELA, and LUCD HeadlinesSourceHeadlineTELA Bio Launches Innovative Hernia Repair Device in the U.S. Marketmsn.com - April 17 at 9:16 AMTELA Bio launches OviTex IHR for inguinal hernia repair in USmsn.com - April 16 at 5:32 PMTELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repairpharmabiz.com - April 16 at 7:29 AMTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Proceduresglobenewswire.com - April 15 at 7:00 AMMDXG: Legal Avenuesfinance.yahoo.com - April 11 at 1:10 PMTELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical Affairsmsn.com - April 10 at 6:58 AMTELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategyfinanznachrichten.de - April 8 at 4:17 PMTELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategyglobenewswire.com - April 8 at 7:00 AMTELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024msn.com - March 25 at 8:23 AMAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Resultsfinance.yahoo.com - March 24 at 5:22 PMTELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 23 at 11:14 PMTELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)finance.yahoo.com - March 23 at 8:39 AMTELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgerystockhouse.com - March 22 at 5:36 PMTELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 22 at 5:36 PMJMP Securities Reiterates Market Outperform Rating for TELA Bio (NASDAQ:TELA)marketbeat.com - March 22 at 2:10 PMPiper Sandler Trims TELA Bio (NASDAQ:TELA) Target Price to $12.00marketbeat.com - March 22 at 10:25 AMQ4 2023 TELA Bio Inc Earnings Callfinance.yahoo.com - March 22 at 7:36 AMRecap: TELA Bio Q4 Earningsbenzinga.com - March 21 at 9:14 PMTELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023msn.com - March 21 at 9:14 PMTELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 21 at 9:14 PMTELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 21 at 6:31 PMStrategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA Biomarkets.businessinsider.com - March 21 at 4:13 PMTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Resultsfinance.yahoo.com - March 21 at 4:13 PMTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Resultsglobenewswire.com - March 21 at 4:05 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeIs DraftKings A Good Bet Ahead of Q1 Earnings?March 27, 2024 10:45 AMView Is DraftKings A Good Bet Ahead of Q1 Earnings?Are Carnival Shares Ready to Set Sail into the $20sApril 2, 2024 8:00 AMView Are Carnival Shares Ready to Set Sail into the $20sAll Headlines Company DescriptionsLMF Acquisition OpportunitiesNASDAQ:LMAOLMF Acquisition Opportunities, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Tampa, Florida.Lucid DiagnosticsNASDAQ:LUCDLucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.NeuroneticsNASDAQ:STIMNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.TELA BioNASDAQ:TELATELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.